Literature DB >> 9819402

Utilization of an NF-ATp binding promoter element for EGR3 expression in T cells but not fibroblasts provides a molecular model for the lymphoid cell-specific effect of cyclosporin A.

H W Mages1, R Baag, B Steiner, R A Kroczek.   

Abstract

Cyclosporin A (CsA) mainly exerts its immunosuppressive action by selectively inhibiting Ca2+/calcineurin-dependent gene transcription in lymphoid cells. A model explaining the tissue-specific effect of this drug on gene expression has not been established to date, since none of the known intracellular targets of CsA (e.g., cyclophilins, calcineurin, and NF-AT) is lymphoid cell specific. To investigate this issue, we performed a detailed comparative analysis of the promoter regulating the two-signal-dependent (Ca2+ ionophore plus phorbol myristate acetate [PMA]), CsA-sensitive expression of EGR3 in T cells and the one-signal-dependent (PMA), CsA-insensitive expression of EGR3 in fibroblasts. As a result, we identified a 27-bp promoter element functionally interacting with transcription factors NF-ATp and NF-ATc that is crucial for the CsA-sensitive expression of the EGR3 gene in T cells. In contrast, the same element was without function in fibroblasts, and other, CsA-insensitive promoter regions were found to be responsible for EGR3 gene expression in these cells. The inactivity of the 27-bp element in fibroblasts was apparently due to insufficient expression levels of NF-ATp, since overexpression of NF-ATp, but not NF-ATc, restored the two-signal phenotype and CsA sensitivity of EGR3 promoter induction in these cells. The differential usage of an NF-AT binding site explains the selective effect of CsA on EGR3 gene expression in T cells versus fibroblasts and may represent one of the basic mechanisms underlying the tissue specificity of CsA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819402      PMCID: PMC109297          DOI: 10.1128/MCB.18.12.7157

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  46 in total

Review 1.  The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation.

Authors:  E Serfling; A Avots; M Neumann
Journal:  Biochim Biophys Acta       Date:  1995-09-19

Review 2.  FK506 and cyclosporin, molecular probes for studying intracellular signal transduction.

Authors:  J Liu
Journal:  Immunol Today       Date:  1993-06

3.  Induction of members of the IL-8/NAP-1 gene family in human T lymphocytes is suppressed by cyclosporin A.

Authors:  P F Zipfel; A Bialonski; C Skerka
Journal:  Biochem Biophys Res Commun       Date:  1991-11-27       Impact factor: 3.575

Review 4.  Transcription factors of the NFAT family: regulation and function.

Authors:  A Rao; C Luo; P G Hogan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

5.  Cooperative interaction of nuclear factor-kappa B- and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines.

Authors:  N Mukaida; Y Mahe; K Matsushima
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

6.  Cyclosporin a modulation of tumor necrosis factor gene expression and effects in vitro and in vivo.

Authors:  D T Nguyen; M K Eskandai; L E DeForge; C L Raiford; R M Strieter; S L Kunkel; D G Remick
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

7.  Cloning of ATAC, an activation-induced, chemokine-related molecule exclusively expressed in CD8+ T lymphocytes.

Authors:  S Müller; B Dorner; U Korthaüer; H W Mages; M D'Apuzzo; G Senger; R A Kroczek
Journal:  Eur J Immunol       Date:  1995-06       Impact factor: 5.532

8.  Neutrophil-activating peptide 1/interleukin 8 mRNA expression and protein secretion by human monocytes: effect of cyclosporin A.

Authors:  U Mrowietz; M Sticherling; V Mielke; J M Schröder; E Christophers
Journal:  Cytokine       Date:  1991-07       Impact factor: 3.861

9.  Cyclosporin A inhibits CD40 ligand expression in T lymphocytes.

Authors:  R Fuleihan; N Ramesh; A Horner; D Ahern; P J Belshaw; D G Alberg; I Stamenkovic; W Harmon; R S Geha
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

10.  Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.

Authors:  B Frantz; E C Nordby; G Bren; N Steffan; C V Paya; R L Kincaid; M J Tocci; S J O'Keefe; E A O'Neill
Journal:  EMBO J       Date:  1994-02-15       Impact factor: 11.598

View more
  4 in total

1.  Vascular endothelial growth factor activation of endothelial cells is mediated by early growth response-3.

Authors:  Jun-ichi Suehiro; Takao Hamakubo; Tatsuhiko Kodama; William C Aird; Takashi Minami
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

2.  Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses.

Authors:  Nathalie M Droin; Michael J Pinkoski; Emmanuel Dejardin; Douglas R Green
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

3.  Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression.

Authors:  Jyothi Rengarajan; Kerri A Mowen; Kathryn D McBride; Erica D Smith; Harinder Singh; Laurie H Glimcher
Journal:  J Exp Med       Date:  2002-04-15       Impact factor: 14.307

Review 4.  Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance.

Authors:  Akiko Yamada; Rieko Arakaki; Masako Saito; Yasusei Kudo; Naozumi Ishimaru
Journal:  Front Immunol       Date:  2017-04-05       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.